Vol. 1 No. 3 (2021)
Health Technology Reviews

Onabotulinum Toxin A (Botox) for Spasticity Associated With Multiple Sclerosis

Published March 8, 2021

Key Messages

  • Evidence-based clinical practice guidelines recommend the use of botulinum toxin (which includes onabotulinum toxin A [Botox]) to treat spasticity caused by multiple sclerosis.
  • There is a lack of recent evidence regarding the clinical and cost-effectiveness of Botox as a treatment for spasticity caused by multiple sclerosis; thus, there is a need for well-designed studies on this topic.